Research Use Only (RUO). This article is for education and shares what published science says about a research compound. It is not medical advice, and nothing here is a suggestion to use any peptide on people or animals.
If you searched retatrutide vs semaglutide or retatrutide vs ozempic, this is a plain, research-based comparison. Both are handled here as Research Use Only reference materials, not medicines.
One target vs three
Semaglutide is a single agonist: it acts on one receptor, GLP-1. It is the peptide behind well-known brands. Retatrutide is a triple agonist: it acts on GLP-1, GIP, and glucagon receptors. So retatrutide adds two more pathways to the single action of semaglutide.
What the trials reported
In the STEP-1 Phase 3 trial, semaglutide reported a mean weight reduction of about 14.9% at 68 weeks at its top studied amount. Retatrutide reported up to 24.2% at 48 weeks in Phase 2 and roughly 28-30% in Phase 3 TRIUMPH. These are separate trials, not a direct comparison, but they show the research interest in the triple-agonist approach.
Approval status
Semaglutide is already approved in several uses. Retatrutide is not FDA approved and is still in Phase 3 as of 2026. Any retatrutide sold today is a research compound.
Is retatrutide better than semaglutide?
Trial numbers are larger for retatrutide, but 'better' depends on the research question, safety data still being gathered, and the fact that the two were tested in different studies. Researchers weigh all of that rather than a single number.
Retatrutide research materials at Dissolv Labs
Dissolv Labs supplies high-purity compounds as reference materials for laboratory research only. They are not for human or animal use.
Frequently asked questions
Is retatrutide the same as Ozempic?
No. Ozempic is a brand of semaglutide (a GLP-1). Retatrutide is a different, investigational triple agonist.
Is retatrutide better than semaglutide?
Trials report larger mean weight changes for retatrutide, but they were separate studies, and retatrutide is not approved.
Can labs study both together?
Yes, comparison research across single, dual, and triple agonists is common. Both are available as RUO reference materials.
The bottom line
Semaglutide acts on one receptor; retatrutide acts on three. Retatrutide's trials report larger mean weight changes, but it remains investigational while semaglutide is established. Both are Research Use Only here.
Sources
- Jastreboff et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (NEJM, via PubMed)
- Eli Lilly: Retatrutide Phase 3 (TRIUMPH) topline results
- AJMC: Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1
- Drugs.com: Retatrutide history and FDA approval status
Disclaimer: All Dissolv Labs products are sold for Research Use Only and are not for human or veterinary use. This content is educational and is not medical advice, diagnosis, treatment guidance, or a recommendation to consume any substance.
